An observational study in Prostate Cancer and Survivorship, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center — 15 open to participants now, 41 under way, 4 of them phase 3. Prostatic Neoplasms · Memorial Sloan Kettering Cancer Center.
Among the 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 13th largest by enrollment of the 24 observational ones that give a count, is one of 3 that started in 2022, is one of 24 observational ones, reaches primary completion later than 23 of the 40 other live ones, and was the 123rd registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Men only
Memorial Sloan Kettering Cancer Center · Sites in United States, Mexico
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 53 · Phase 3 8
First in 1990; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is close to the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 51 across the 99 interventional studies, 201 across the 24 observational. Of the 92 that completed or were terminated, 22 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
27 of the studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03574571Phase 3Memorial Sloan Kettering Cancer CenterA Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | 2027-04-01 |
| NCT01407263Phase 3Memorial Sloan Kettering Cancer CenterTrial of Modifications to Radical Prostatectomy | 2027-07 |
| NCT02706561Memorial Sloan Kettering Cancer CenterHelping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery | 2026-12 |
| NCT00578240Memorial Sloan Kettering Cancer CenterMolecular Studies and Clinical Correlations in Human Prostatic Disease | 2026-12 |
| NCT02312401Memorial Sloan Kettering Cancer CenterEvaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy | 2026-12 |
Add all 27 to your calendar (.ics) → With an account.
Among the 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect information that may help the researchers understand the relationship between prostate cancer survivors' experiences of cancer-related cognitive dysfunction (CRCD) and their other conditions (co-morbid factors), including anxiety, depression, and insomnia. The researchers will also find out how additional things may contribute to CRCD, including social factors, the characteristics of participants' prostate cancer, and the type of cancer treatment or other medications they received.
Patients from Memorial Sloan Kettering Cancer Center (MSK) and the Ralph Lauren Center (RLC), an MSK-affiliated Harlem community clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a cross-sectional study with a one-time data collection process and no subsequent follow-ups. If patients did not opt out of receiving study-specific text communications, they may also receive text messages with reminders about surveys and/or direct links to REDCap to complete the surveys. Text-based communications will be delivered using the secure, HIPAA-compliant Mosio texting platform developed for clinical research.
Behavioral: PROMIS-SF v2.0 -Cognitive Function 8a
Patient-Reported Outcomes (PROs)
number of participants with co-morbid symptoms
All participants will be evaluable as long as they have completed the PROMIS-SF v2.0 - Cognitive Function 8a.
Time frame: 1 year
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Sep 2022 (actual). Primary completion is estimated for Sep 2027, 60 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →